CN118005609A - 2-Aminopyrimidine compound and application thereof - Google Patents
2-Aminopyrimidine compound and application thereof Download PDFInfo
- Publication number
- CN118005609A CN118005609A CN202211399109.8A CN202211399109A CN118005609A CN 118005609 A CN118005609 A CN 118005609A CN 202211399109 A CN202211399109 A CN 202211399109A CN 118005609 A CN118005609 A CN 118005609A
- Authority
- CN
- China
- Prior art keywords
- amino
- phenyl
- piperidin
- piperazine
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 2-Aminopyrimidine compound Chemical class 0.000 title claims description 147
- 150000001875 compounds Chemical class 0.000 claims abstract description 62
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000000651 prodrug Substances 0.000 claims abstract description 16
- 229940002612 prodrug Drugs 0.000 claims abstract description 16
- 239000012453 solvate Substances 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 11
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims abstract description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 10
- 150000005006 2-aminopyrimidines Chemical class 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 54
- 229910052736 halogen Inorganic materials 0.000 claims description 45
- 150000002367 halogens Chemical class 0.000 claims description 45
- 125000000623 heterocyclic group Chemical group 0.000 claims description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 claims description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 17
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 16
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 16
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 16
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 16
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 13
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 12
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 11
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims description 8
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 8
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims description 6
- 206010066476 Haematological malignancy Diseases 0.000 claims description 5
- 102000042838 JAK family Human genes 0.000 claims description 5
- 108091082332 JAK family Proteins 0.000 claims description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 206010028537 myelofibrosis Diseases 0.000 claims description 4
- 208000037244 polycythemia vera Diseases 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 claims description 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 abstract description 41
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 91
- 238000003786 synthesis reaction Methods 0.000 description 91
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 31
- 238000000034 method Methods 0.000 description 31
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 29
- 238000001308 synthesis method Methods 0.000 description 18
- DQXNTSXKIUZJJS-UHFFFAOYSA-N 2,4-dichloro-5-methylpyrimidine Chemical compound CC1=CN=C(Cl)N=C1Cl DQXNTSXKIUZJJS-UHFFFAOYSA-N 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 15
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 15
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 15
- 239000002994 raw material Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 9
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 6
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 5
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229950003487 fedratinib Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 208000014951 hematologic disease Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 3
- 208000036566 Erythroleukaemia Diseases 0.000 description 3
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000021841 acute erythroid leukemia Diseases 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- GVWISOJSERXQBM-UHFFFAOYSA-N n-methylpropan-1-amine Chemical compound CCCNC GVWISOJSERXQBM-UHFFFAOYSA-N 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical group NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- JSOMVCDXPUXKIC-UHFFFAOYSA-N tert-butyl 3-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)C1 JSOMVCDXPUXKIC-UHFFFAOYSA-N 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- GPRYKVSEZCQIHD-UHFFFAOYSA-N 1-(4-aminophenyl)ethanone Chemical compound CC(=O)C1=CC=C(N)C=C1 GPRYKVSEZCQIHD-UHFFFAOYSA-N 0.000 description 1
- GGYVTHJIUNGKFZ-UHFFFAOYSA-N 1-methylpiperidin-2-one Chemical compound CN1CCCCC1=O GGYVTHJIUNGKFZ-UHFFFAOYSA-N 0.000 description 1
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
- XOZAJNLUAODXSP-UHFFFAOYSA-N 2-fluoro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(F)N=C1 XOZAJNLUAODXSP-UHFFFAOYSA-N 0.000 description 1
- HYDDAQBDCYWJQC-UHFFFAOYSA-N 4-(4-morpholin-4-ylpiperidin-1-yl)aniline Chemical compound C1=CC(N)=CC=C1N1CCC(N2CCOCC2)CC1 HYDDAQBDCYWJQC-UHFFFAOYSA-N 0.000 description 1
- GXFBCIIDDSTHOT-UHFFFAOYSA-N 4-[1-(4-nitrophenyl)piperidin-4-yl]morpholine Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1CCC(N2CCOCC2)CC1 GXFBCIIDDSTHOT-UHFFFAOYSA-N 0.000 description 1
- YYBXNWIRMJXEQJ-UHFFFAOYSA-N 4-piperidin-4-ylmorpholine Chemical compound C1CNCCC1N1CCOCC1 YYBXNWIRMJXEQJ-UHFFFAOYSA-N 0.000 description 1
- CGFYNRVHPARGFY-UHFFFAOYSA-N 5-fluoro-2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(F)C=N1 CGFYNRVHPARGFY-UHFFFAOYSA-N 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100335080 Homo sapiens FLT3 gene Proteins 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940125436 dual inhibitor Drugs 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- VMPIPCOGRWYUDT-UHFFFAOYSA-N ethyl acetate;oxolane;hydrate Chemical compound O.C1CCOC1.CCOC(C)=O VMPIPCOGRWYUDT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 1
- 229950011410 pacritinib Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical class NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- LETGZXPZNAIRNJ-UHFFFAOYSA-N phenyl n-(4-acetylphenyl)carbamate Chemical compound C1=CC(C(=O)C)=CC=C1NC(=O)OC1=CC=CC=C1 LETGZXPZNAIRNJ-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 102200087780 rs77375493 Human genes 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- JBWQUSZFCONMDT-UHFFFAOYSA-N tert-butyl 4-morpholin-4-ylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1CCOCC1 JBWQUSZFCONMDT-UHFFFAOYSA-N 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention relates to 2-aminopyrimidine compounds shown in a general formula I and pharmaceutically acceptable salts, solvates or prodrugs thereof, a preparation method thereof and a pharmaceutical composition containing the compounds, wherein R 1、R2 and Ar, X, Y, Z, m, n have the meanings given in the specification. The invention also relates to the use of the compounds of formula I for producing medicaments for the treatment and/or prophylaxis of hematological malignancies and inflammatory bowel diseases.
Description
Technical Field
The invention relates to the field of pharmaceutical chemistry, in particular to a 2-aminopyrimidine compound and application thereof in preparing medicaments for treating and/or preventing malignant blood diseases and other proliferative diseases.
Background
Hematological malignancies are a group of malignant clonal diseases originating in the tissue domain of the hematopoietic system, mainly including myelodysplastic syndrome, myeloproliferative diseases, malignant lymphomas, leukemias, and the like. Among them, acute myeloid leukemia (acute myeloid leukemia, AML) is mainly characterized by the retardation of differentiation of bone marrow from external Zhou Zhongyuan progenitor and naive myeloid cells, leading to abnormal proliferation and accumulation of primitive myeloid cells at different differentiation stages, while the production of normal functioning erythrocytes, platelets and leukocytes is drastically reduced. AML is common in all ages, especially in the elderly (> 60 years). In recent years, the incidence rate has been generally increasing, and there is a tendency to be younger.
The Janus kinase (Janus kinases, JAKs)/signal transduction and transcription activator (signal transducer and activator of transcription, STAT) signal pathway is a downstream pathway of numerous cytokine signal transduction, and is widely involved in the processes of proliferation, differentiation, apoptosis, inflammation, etc. of cells. Activation of this pathway is closely related to the development and progression of a variety of diseases, particularly hematological neoplasms and inflammation. JAKs include four subtypes JAK1, JAK2, JAK3, and TYK 2. Among them, JAK2 alone mediates cytokines such as erythropoietin (Erythropoietin, EPO), which forms a signal transduction pathway with downstream STAT5, and plays an important role in the process of bone marrow, erythrocytes and platelets production. When JAK2 levels are elevated or mutated in humans (a common JAK2-V617F mutation), it causes excessive activation of the JAK2-STAT5 pathway, thereby causing the development of hematological malignancies.
Inflammatory bowel disease (inflammatory bowel disease, IBD) is a chronic inflammatory disease with a prevalence of about 0.3% affecting the small intestine, colon and rectum, including both ulcerative colitis and crohn's disease types. In IBD, IL-6, IL-12 and IL-23 are important drivers of disease activity. Among these inflammatory factors, IL-6 signaling is through the JAK1/JAK2/TYK2-STAT3 pathway, and IL-12 and IL-23 signaling is dependent on the JAK2/TYK2-STAT4 pathway. Thus, JAK/STAT pathway signaling is one of the major targets for the treatment of IBD.
FMS-like tyrosine kinase 3 (FMS like tyrosine kinase, FLT 3) is an important type III receptor tyrosine kinase that plays an important role in the proliferation, survival and differentiation of multifunctional hematopoietic stem cells. FLT3 is highly expressed in tumor cells in nearly 90% of AML patients, with mutations in FLT3 gene in about 30% of AML patients. With the development of this class of inhibitors, point mutations in the FLT3 kinase domain (FLT 3-TKD, mainly secondary mutations at residues F691 and D835) have become the leading cause of clinically acquired resistance to FLT3 inhibitors. Thus, inhibition of FLT3 and mutants thereof is an effective method for the treatment of related hematological disorders, in particular AML.
Abnormal activation of JAK2 and FLT3 is closely related to the occurrence of hematological malignancy, and both have a synergistic effect. Therefore, the selective JAK2/FLT3 dual inhibitor can synergistically and downwards regulate the content of p-STAT5, more effectively control the development process of AML, overcome the acquired drug resistance problem faced by single inhibition of FLT3 and reduce the generation of adverse reactions, and is a new field for treating the diseases.
Currently approved marketed JAK2/FLT3 small molecule inhibitors are Pacritinib and Fedratinib. Of these Fedratinib is a dual JAK2/FLT3 inhibitor developed by Impact Biomedicines, with IC 50 values for FLT3 and JAK2 of 15nM and 3nM, respectively, and month 2019 approved by the FDA for the treatment of moderate or high risk primary or acquired (post-polycythemia vera or post-primary thrombocythemia) myelofibrosis adult patients.
Based on previous studies, the present inventors have designed and synthesized a series of compounds having improved selectivity and high inhibitory activity.
The invention comprises the following steps:
The invention aims at a 2-aminopyrimidine compound and application thereof in preparing a medicament for treating and/or preventing malignant blood diseases and other proliferative diseases.
In order to achieve the above purpose, the invention adopts the technical scheme that:
2-aminopyrimidine compounds, wherein the compounds are 2-aminopyrimidine compounds of general formula I and pharmaceutically acceptable salts, solvates or prodrugs thereof,
Wherein,
R 1 is independently selected from hydrogen, halogen, (C 1-C6) alkyl, (C 1-C6) haloalkyl;
Ar is (C 6-C10) aryl, 5-10 membered heteroaryl, optionally substituted with 1-3R 3, which may be the same or different;
R 3 is hydroxy, halogen, nitro, amino, cyano, (C 1-C6) alkyl, (C 1-C6) alkoxy, (C 1-C6) alkyl or (C 1-C6) alkoxy optionally substituted by hydroxy or amino or halogen, (C 1-C6) alkylamido, amino substituted by 1-2 (C 1-C6) alkyl groups, free or salified or esterified or amidated carboxy, (C 1-C6) alkylsulfinyl, (C 1-C6) alkylsulfonyl, (C 1-C6) alkanoyl, carbamoyl substituted by 1-2 (C 1-C6) alkyl, (C 1-C3) alkylenedioxy, (C 6-C10) aryl, (C 3-C10) cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocyclyl;
m and n are each independently an integer between 1 and 3;
Y and Z are each independently selected from N or CH;
X is N or CH;
R 2 is-NR 4R5 when X is CH, R 2 is a 4-10 membered heterocyclic group when X is N;
R 4 and R 5 are the same or different and are each independently selected from hydrogen, (C 1-C6) alkyl, (C 3-C7) cycloalkyl, (C 1-C6) alkanoyl, (C 1-C6) alkyl optionally substituted by hydroxy or amino or halogen; or R 4 and R 5 together with the N atom to which they are attached form a 4-10 membered heterocyclyl or a 5-10 membered heteroaryl;
The heterocyclic or heteroaryl groups in the foregoing R 2、R4 and R 5 are optionally substituted with 0-3R 6, which may be the same or different; the heterocyclic group or heteroaryl group optionally contains 1-4 heteroatoms which are the same or different and are selected from N, O, S, wherein the heterocyclic group optionally comprises 0-2 carbon-carbon double bonds or carbon-carbon triple bonds;
R 6 is oxo, halogen, (C 1-C6) alkyl or (C 1-C6) alkanoyl.
Preferably, the 2-aminopyrimidine compound in the general formula I and pharmaceutically acceptable salts, solvates or prodrugs thereof,
Wherein,
R 1 is independently selected from hydrogen, halogen, (C 1-C4) alkyl, (C 1-C4) haloalkyl;
Ar is (C 6-C10) aryl, 5-6 membered heteroaryl, optionally substituted with 1-3R 3, which may be the same or different;
R 3 is hydroxy, halogen, nitro, amino, cyano, (C 1-C4) alkyl, (C 1-C4) alkoxy, (C 1-C4) alkyl or (C 1-C4) alkoxy optionally substituted by hydroxy or amino or halogen, (C 1-C4) alkylamido, amino substituted by 1-2 (C 1-C4) alkyl groups, free or salified or esterified or amidated carboxy, (C 1-C4) alkylsulfinyl, (C 1-C4) alkylsulfonyl, (C 1-C4) alkanoyl, carbamoyl substituted by 1-2 (C 1-C4) alkyl, (C 1-C3) alkylenedioxy, (C 6-C10) aryl, (C 3-C7) cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl;
m and n are each independently an integer between 1 and 3;
Y and Z are each independently selected from N or CH;
X is N or CH;
R 2 is-NR 4R5, 4-6 membered heterocyclyl or 5-6 membered heteroaryl, when X is N, R 2 is not NR 4R5;
r 4 and R 5 are the same or different and are each independently selected from hydrogen, (C 1-C4) alkyl, (C 3-C7) cycloalkyl, (C 1-C4) alkanoyl, (C 1-C4) alkyl optionally substituted by hydroxy or amino or halogen; or R 4 and R 5 together with the N atom to which they are attached form a 4-6 membered heterocyclyl;
The heterocyclic groups in the foregoing R 2、R4 and R 5 are optionally substituted with 0 to 3R 6, which are the same or different; the heterocyclic group optionally contains 1-4 heteroatoms which are the same or different and are selected from N, O, S, and optionally contains 0-2 carbon-carbon double bonds or carbon-carbon triple bonds;
R 6 is oxo, halogen, (C 1-C6) alkyl, (C 1-C6) alkanoyl.
Preferably, the 2-aminopyrimidine compound in the general formula I and pharmaceutically acceptable salts, solvates or prodrugs thereof,
Wherein,
R 1 is independently selected from hydrogen, halogen, (C 1-C4) alkyl, trifluoromethyl;
Ar is (C 6-C10) aryl, 5-6 membered heteroaryl, optionally substituted with 1-3R 3, which may be the same or different;
R 3 is hydroxy, halogen, nitro, amino, cyano, (C 1-C4) alkyl, (C 1-C4) alkoxy, (C 1-C4) alkyl optionally substituted by hydroxy or amino or halogen or (C 1-C4) alkoxy, (C 1-C4) alkylamido, free or salified or esterified or amidated carboxy, (C 1-C4) alkylsulfinyl, (C 1-C4) alkylsulfonyl, (C 1-C4) alkanoyl, carbamoyl substituted by 1-2 (C 1-C4) alkyl, (C 1-C3) alkylenedioxy, (C 3-C6) cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl;
m and n are each independently 1 or 2;
Y and Z are each independently selected from N or CH;
X is CH;
R 2 is-NR 4R5;
R 4 and R 5 are the same or different and are each independently selected from hydrogen, (C 1-C4) alkyl, (C 3-C6) cycloalkyl, (C 1-C4) alkanoyl, (C 1-C4) alkyl optionally substituted by hydroxy, amino or halogen; or R 4 and R 5 together with the N atom to which they are attached form a 4-6 membered heterocyclyl;
The heterocyclic groups in the foregoing R 2、R4 and R 5 are optionally substituted with 0 to 3R 6, which are the same or different; the heterocyclic group optionally contains 1-4 heteroatoms which are the same or different and are selected from N, O, S, and optionally contains 0-2 carbon-carbon double bonds or carbon-carbon triple bonds;
R 6 is oxo, halogen, (C 1-C4) alkyl, (C 1-C4) alkanoyl.
Further preferred, the 2-aminopyrimidine compound of the general formula I and pharmaceutically acceptable salts, solvates or prodrugs thereof,
Wherein X is C;
m and n are the same or different and are 1 or 2;
r 1 is independently selected from hydrogen, halogen, (C 1-C4) alkyl, trifluoromethyl;
Ar is (C 6-C10) aryl, 5-6 membered heteroaryl, optionally substituted with 1-3R 3, which may be the same or different;
R 3 is hydroxy, halogen, nitro, amino, cyano, (C 1-C4) alkyl, (C 1-C4) alkoxy, (C 1-C4) alkyl optionally substituted by hydroxy, amino or halogen or (C 1-C4) alkoxy, (C 1-C4) amino substituted by 1-2 (C 1-C4) alkyl, (C 1-C4) alkylamido, free or salified or esterified or amidated carboxy, (C 1-C4) alkylsulfinyl, (C 1-C4) alkylsulfonyl, (C 1-C4) alkanoyl, carbamoyl substituted by 1-2 (C 1-C4) alkyl, (C 1-C3) alkylenedioxy, (C 3-C6) cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl;
Y and Z are each independently selected from N or CH;
R 4 and R 5 are the same or different and are each independently selected from (C 1-C4) alkyl, (C 1-C4) alkyl optionally substituted by hydroxy; or R 4 and R 5 together with the N atom to which they are attached form a 4-6 membered heterocyclyl;
The heterocyclic group is optionally substituted with 0 to 3 identical or different R 6; the heterocyclic group optionally contains 1-4 heteroatoms which are the same or different and are selected from N, O, S, and optionally contains 0-2 carbon-carbon double bonds or carbon-carbon triple bonds;
R 6 is oxo, halogen, (C 1-C4) alkyl, (C 1-C4) alkanoyl.
Still further preferred, the 2-aminopyrimidine compounds of the general formula I and pharmaceutically acceptable salts, solvates or prodrugs thereof,
R 1 is independently selected from hydrogen, halogen, (C 1-C4) alkyl;
X is C;
m and n are the same or different and are 1 or 2;
Ar is phenyl optionally substituted with 1 to 3R 3, which may be the same or different;
R 3 is hydroxy, halogen, nitro, amino, cyano, (C 1-C4) alkyl, (C 1-C4) alkoxy, (C 1-C4) alkyl optionally substituted by hydroxy, amino or halogen or (C 1-C4) alkoxy, (C 1-C4) alkylamido, free, salified, esterified and amidated carboxy, (C 1-C4) alkylsulfinyl, (C 1-C4) alkylsulfonyl, (C 1-C4) alkanoyl, (C 1-C4) alkylcarbamoyl, (C 1-C3) alkylenedioxy, imidazolyl, pyrazolyl, triazolyl, oxazolyl, isoxazolyl, oxadiazolyl;
Y and Z are CH;
R 4 and R 5 are the same or different and are each independently selected from (C 1-C4) alkyl, (C 1-C4) alkyl optionally substituted by hydroxy; or R 4 and R 5 together with the N atom to which they are attached form
More preferably, 2-aminopyrimidines of formula I:
n- (4-acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- (4-acetylphenyl) -4- [2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- (4-acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- (4-acetylphenyl) -4- [2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- (4-acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (piperidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (piperidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [2- ({ 4- [4- (piperidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- (4-acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- { 5-chloro-2- [ (4- {4- [ (2-hydroxyethyl) (methyl) amino ] piperidin-1-yl } phenyl) amino ] pyrimidin-4-yl } piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- { 5-chloro-2- [ (4- {4- [ (methyl) (propyl) amino ] piperidin-1-yl } phenyl) amino ] pyrimidin-4-yl } piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- { 5-chloro-2- ({ 4- [3- (morpholin-4-yl) pyrrolidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- { 5-chloro-2- [ (4- {3- [ (2-hydroxyethyl) (methyl) amino ] pyrrolidin-1-yl } phenyl) amino ] pyrimidin-4-yl } piperazine-1-carboxamide;
n- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
The compounds of formula I of the present invention may form pharmaceutically acceptable salts thereof with acids according to some general methods in the art to which the present invention pertains. Preferred acids are hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, trifluoroacetic acid and aspartic acid.
The invention also includes prodrugs of the derivatives of the invention. Prodrugs of the derivatives of the invention are derivatives of formula I which may themselves have a relatively weak or even no activity, but are converted to the corresponding biologically active form after administration under physiological conditions (e.g. by metabolism, solvolysis or otherwise).
The term "halogen" as used herein, unless otherwise indicated, refers to fluorine, chlorine or bromine; "alkyl" refers to a straight or branched chain alkyl group; "cycloalkyl" refers to a substituted or unsubstituted cycloalkyl; "alkoxy" refers to straight or branched chain alkoxy; "alkenyl" refers to straight or branched chain alkenyl groups; "alkynyl" refers to straight or branched chain alkynyl groups; "aryl" refers to phenyl groups that are unsubstituted or substituted; "heteroaryl" means a monocyclic or polycyclic ring system containing one or more heteroatoms selected from N, O, S, the ring system being aromatic, such as imidazolyl, pyridyl, pyrazolyl, furanyl, thienyl, pyrrolyl, thiazolyl, benzothiazolyl, oxazolyl, isoxazolyl, naphthyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolyl, and the like; "saturated or partially saturated heterocyclyl" refers to a monocyclic or polycyclic ring system containing one or more heteroatoms selected from N, O, S, such as pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, pyrazolidinyl, imidazolidinyl, thiazolinyl, and the like.
The invention also includes pharmaceutical compositions comprising as active ingredient a compound of formula I and pharmaceutically acceptable salts and/or solvates thereof, in combination with a pharmaceutically acceptable carrier; the compounds of the invention may be used in combination with other active ingredients as long as they do not produce other adverse effects, such as allergic reactions.
The carriers used in the pharmaceutical compositions of the invention are of the usual types available in the pharmaceutical arts, including: binders, lubricants, disintegrants, cosolvents, diluents, stabilizers, suspending agents, pigment-free agents, flavoring agents and the like for oral preparations; preservatives, solubilizing agents, stabilizers and the like for injectable formulations; matrix for topical formulations, diluents, lubricants, preservatives and the like. Pharmaceutical formulations may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically), and if some drugs are unstable under gastric conditions, they may be formulated as enteric coated tablets.
Through enzyme activity tests of JAK2, JAK3 and FLT3, the compound has remarkable JAK2 and FLT3 inhibiting activity, has a strong inhibiting effect on blood cancer cells with high expression of JAK2 or FLT3, and improves selectivity of partial compounds.
Through in vitro experiments of inhibiting the activity of human erythroleukemia cells HEL and human myelomonocytic leukemia cells MV4-11, the compounds have remarkable anti-tumor activity, so that the compounds can be used for preparing medicines for treating or preventing various proliferative diseases or malignant blood diseases, such as myelofibrosis, multiple myeloma, polycythemia vera, essential thrombocythemia, acute myelogenous leukemia, acute lymphoblastic leukemia and the like.
The precise amount of a compound of the invention required to treat inflammatory bowel disease or hematological malignancy will vary from subject to subject, depending on the type of subject, the age and general condition, the severity of the condition being treated, the particular compound used, and the mode of administration, e.g., route and frequency of administration, and the like. One of ordinary skill in the art can determine the appropriate effective amount using only routine experimentation.
The hematological malignancy includes: leukemia, myelodysplastic syndrome, malignant lymphoma, multiple myeloma, and myeloproliferative diseases.
The leukemia comprises: acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphoblastic leukemia, and chronic myeloid leukemia.
The myeloproliferative disease includes: polycythemia vera, chronic myelogenous leukemia, primary thrombocythemia and myelofibrosis.
The inflammatory bowel disease includes: ulcerative colitis and Crohn's disease.
The amount of the compound administered may be from about 0.1 to 100mg/kg body weight per day, preferably 1 to 50mg/kg body weight per day. It will be appreciated that the dosage may vary depending on the patient's requirements, the severity of the proliferative disease or hematological malignancy being treated, and the particular compound being used. Moreover, it will be appreciated that the initial dose administered may be increased beyond an upper limit in order to rapidly reach the desired blood level, or the initial dose may be less than optimal, and the daily dose may be gradually increased during treatment, depending on the particular situation. If desired, the daily dose may also be divided into multiple doses, for example 2-4 times per day.
Mammal means a human or an animal.
The amount of active ingredient, i.e. the compound according to the invention, in the pharmaceutical composition and unit dosage forms thereof may vary depending on the particular application, the potency of the particular compound and the desired concentration. Generally, the content of active ingredient will be between 0.5% and 90% by total weight of the composition.
In combination therapy, the compound of the invention and the other compound may be administered simultaneously or separately, and in the case of simultaneous administration, the compound of the invention and the other compound may be combined in a single pharmaceutical composition or in separate compositions.
The examples and preparations provided below further illustrate and exemplify the compounds of the invention and methods of preparing the same. It should be understood that the scope of the following examples and preparations is not intended to limit the scope of the present invention in any way.
The following synthetic schemes describe the preparation of the derivatives of formula I of the present invention, all starting materials being prepared by the methods described in these schemes, by methods well known to those of ordinary skill in the art of organic chemistry, or are commercially available. All of the final compounds of the present invention are prepared by the methods described in these schemes or by methods analogous thereto, which are well known to those of ordinary skill in the art of organic chemistry. All variable factors applied in these schematic drawings are as defined below or as defined in the claims.
The derivatives of the general formula I according to the invention are exemplified in the present synthetic route by the following compounds: the definition of the substituent R 1、R4、R5 and Y, Z, m, n, ar is the same as that of the claims.
Synthesis of Compound I-I
In the route A, the aromatic amine A and phenyl chloroformate undergo a condensation reaction to obtain an intermediate B; the intermediate C and small molecular amine undergo reductive amination reaction to obtain an intermediate D, and then the intermediate D is subjected to Boc removal protection, substitution and reduction to obtain an intermediate H; the intermediate I and N-Boc piperazine undergo substitution reaction to obtain an intermediate J, and the intermediate H and the intermediate J undergo nucleophilic substitution and Boc protection removal to form urea to obtain a target compound I-I
Synthesis of Compound I-ii
In the route B, the aromatic amine A and phenyl chloroformate undergo a condensation reaction to obtain an intermediate B; the intermediate M and small molecular amine undergo reductive amination reaction to obtain an intermediate N, and then the intermediate N is subjected to Boc removal protection, substitution and reduction to obtain an intermediate Q; and carrying out substitution reaction on the intermediate I and N-Boc piperazine to obtain an intermediate J, and carrying out nucleophilic substitution on the intermediate Q and the intermediate J to remove Boc protection and form urea to obtain the target compound I-ii.
The specific embodiment is as follows:
in the examples below, the methods of preparing some of the compounds are depicted. It will be appreciated that the following methods, as well as other methods known to those of ordinary skill in the art, may be applicable to the preparation of all compounds described herein. The examples are intended to illustrate, but not limit the scope of the invention. The nuclear magnetic resonance hydrogen spectrum of the compound is measured by Bruker ARX-600, and the mass spectrum is measured by Agilent 1100 LC/MSD; the reagents used are analytically pure or chemically pure. The compounds of examples 1-35 were prepared by reacting various substituted phenyl carbamates B starting from intermediate L or intermediate S according to the procedure of example 1.
EXAMPLE 1 preparation of N- (4-Acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
Synthesis of tert-butyl 4- (morpholin-4-yl) piperidine-1-carboxylate (D)
N-Boc-4-piperidone (2.0 g,10.04 mmol), morpholine (1.05 g,12.05 mmol) and acetic acid (0.72 g,12.05 mmol) were dissolved in methanol (20 mL) at room temperature and stirred for 4h, after which sodium cyanoborohydride (1.89 g,30.12 mmol) was added and the reaction was continued for 6h. After the completion of the reaction, 10% aqueous sodium hydrogencarbonate (20 mL) was added to quench, the organic solvent was distilled off under reduced pressure, the aqueous phase was extracted with ethyl acetate (20 mL. Times.3), the organic phase was collected, and the organic solvent was distilled off under reduced pressure to give 2.0g of a yellow oil, yield 74.1%.
Synthesis of 4- (piperidin-4-yl) morpholine (E)
Intermediate D (2.0 g,7.41 mmol) was dissolved in 1, 4-dioxane (10 mL) at room temperature, dioxane hydrogen chloride solution (10 mL) was slowly added, and the reaction was completed at room temperature for 4h. After the reaction, a small amount of 1, 4-dioxane (2 mL) was used for washing the filter cake, and the filter cake was dried to obtain 1.1g of a white solid with a yield of 87.3%.
1.3.4- [1- (4-Nitrophenyl) piperidin-4-yl ] morpholine (G)
Intermediate E (1 g,4.84 mmol), p-fluoronitrobenzene (0.72 g,5.08 mmol) and anhydrous potassium carbonate (2.0 g,14.52 mmol) were dissolved in DMSO (10 mL) at room temperature and warmed to 80℃for 4h. After the reaction, water (20 mL) was added, the aqueous phase was extracted with ethyl acetate (20 ml×3), the organic phase was collected, washed with aqueous lithium chloride (20 ml×3), the organic solvent was distilled off under reduced pressure, and purified by column chromatography (DCM: meoh=20:1) to give 1.0g of yellow solid in 71.4% yield.
1.4.4- [4- (Morpholin-4-yl) piperidin-1-yl ] aniline (H)
Intermediate G (1.0G, 3.44 mmol) and 55% palladium on carbon (0.1G) were dissolved in absolute ethanol (10 mL) at room temperature under hydrogen and reacted at room temperature for 6h. After the reaction, the filter cake was washed with ethanol (20 mL) and the filtrate was collected and distilled off under reduced pressure to give 0.6g of a brown solid, which was dried, with a yield of 67.4%.
Synthesis of 1.5.4- (2, 4, 5-trichloropyrimidin-4-yl) piperazine-1-carboxylic acid tert-butyl ester (J)
2,4, 5-Trichloropyrimidine (20.0 g,110 mmol) was dissolved in DMF (200 mL), potassium carbonate (19.0 g,132 mmol) was added, N-Boc-piperazine (21.5 g,115.5 mmol) was added in portions, and the reaction was completed at room temperature for 2h. After the completion of the reaction, water (1L) was added to the reaction mixture, followed by stirring, suction filtration, washing of the cake with water (100 mL) and drying to give 30.0g of a white solid, with a yield of 82.2%.
Synthesis of 1.6.4-chloro-2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxylic acid tert-butyl ester (K)
Intermediate J (0.5 g,1.92 mmol) and intermediate H (0.67 g,2.02 mmol) were dissolved in isopropanol (5 mL) at room temperature, trifluoroacetic acid (0.66 g,5.76 mmol) was added and the temperature was raised to 85℃for 6H. After the completion of the reaction, the solvent was concentrated under reduced pressure, water (10 mL) was added to the residue, the pH was adjusted to 8 with saturated sodium bicarbonate solution, suction filtration was performed, the cake was washed with water (20 mL), and dried to give 0.7g of a white solid with a yield of 66%.
Synthesis of N- (4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl) -5-chloro-4- (piperazin-1-yl) pyrimidin-2-amine (L)
Intermediate K (0.7 g 1.26 mmol) was added to 7mL of dichloromethane at room temperature, 7mL of trifluoroacetic acid was slowly added dropwise, and the reaction was carried out at room temperature for 4h. After the completion of the reaction, the solution was concentrated under reduced pressure, water (5 mL) was added to the residue, the pH was adjusted to 10 with a 20% sodium hydroxide solution, suction filtration was performed, the cake was washed with water (20 mL), and 0.5g of a gray solid was obtained after drying, and the yield was 87.7%.
Synthesis of phenyl N- (4-acetylphenyl) carbamate (B)
To a mixed solution of ethyl acetate-tetrahydrofuran-water (3:1:1, 200 mL) was added (20 g,148 mmol) of 4-aminoacetophenone and (9.42 g,88.8 mmol) of sodium carbonate at room temperature, phenyl chloroformate (27.7 g,178 mmol) was added dropwise under ice bath, and the mixture was reacted at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure, water (100 mL) was added to the residue, the pH was adjusted to 5 with 1M hydrochloric acid solution, suction filtration was performed, and the cake was washed with water (100 mL) and dried to give 30g of a white solid in a yield of 81.1%.
Synthesis of N- (4-acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide (I)
Intermediate L (0.2 g,0.44 mmol), DIPEA (0.07 g,0.53 mmol) and intermediate B (0.13 g,0.53 mmol) were added to 1, 4-dioxane (2 mL) at room temperature and allowed to react at 80℃for 4h. After the reaction, the mixture was cooled to room temperature, the solvent was concentrated under reduced pressure, water (5 mL) was added to the residue, pH was adjusted to 10 with 5% NaOH solution, and the mixture was suction-filtered and dried to obtain a crude product. The crude product was purified by column chromatography (dichloromethane: methanol=20:1) to give 0.15g of a white solid in 55.6% yield.
EXAMPLE 2 preparation of N- (4-Acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate L was synthesized following the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloro-5-methylpyrimidine, followed by N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide following the synthesis of 1.9 in example 1. The yield thereof was found to be 61.2%.
EXAMPLE 3 preparation of N- (4-Acetylphenyl) -4- [2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloropyrimidine, and N- (4-acetylphenyl) -4- [2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 58.7%.
EXAMPLE 4 preparation of N- (4-Acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from N-methylpiperazine, N-Boc-4-piperidone and p-fluoronitrobenzene, the key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2,4, 5-trichloropyrimidine, and finally N- (4-acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 62.7%.
EXAMPLE 5 preparation of N- (4-Acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from N-methylpiperazine, N-Boc-4-piperidone and p-fluoronitrobenzene, the key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloro-5-methylpyrimidine, and finally N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 65.1%.
EXAMPLE 6 preparation of N- (4-Acetylphenyl) -4- [2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized from N-methylpiperazine, N-Boc-4-piperidone and p-fluoronitrobenzene according to the method of synthesis of 1.1-1.4 in example 1, the key intermediate L was synthesized from 2, 4-dichloropyrimidine according to the method of synthesis of 1.5-1.7 in example 1, and finally N- (4-acetylphenyl) -4- [2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the method of synthesis of 1.9 in example 1. The yield thereof was found to be 56.5%.
EXAMPLE 7 preparation of N- (4-Acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized from tetrahydropyrrole, N-Boc-4-piperidone and p-fluoronitrobenzene according to the method of synthesis of 1.1-1.4 in example 1, then 2,4, 5-trichloropyrimidine was used as the starting material, the key intermediate L was synthesized according to the method of synthesis of 1.5-1.7 in example 1, and finally N- (4-acetylphenyl) -4- [2- ({ 4- [4- (4-pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the method of synthesis of 1.9 in example 1. The yield thereof was found to be 63.5%.
EXAMPLE 8 preparation of N- (4-Acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized from tetrahydropyrrole, N-Boc-4-piperidone and p-fluoronitrobenzene according to the method of synthesis of 1.1-1.4 in example 1, then 2, 4-dichloro-5-methylpyrimidine was used as the raw material, the key intermediate L was synthesized according to the method of synthesis of 1.5-1.7 in example 1, and finally N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the method of synthesis of 1.9 in example 1. The yield thereof was found to be 68.1%.
EXAMPLE 9 preparation of N- (4-Acetylphenyl) -4- [2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized from tetrahydropyrrole, N-Boc-4-piperidone and p-fluoronitrobenzene according to the method of synthesis of 1.1-1.4 in example 1, the key intermediate L was synthesized from 2, 4-dichloropyrimidine according to the method of synthesis of 1.5-1.7 in example 1, and finally N- (4-acetylphenyl) -4- [2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the method of synthesis of 1.9 in example 1. The yield thereof was found to be 70.4%.
EXAMPLE 10 preparation of N- (4-Acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (piperidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting with piperidine, N-Boc-4-piperidone and p-fluoronitrobenzene, the key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting with 2,4, 5-trichloropyrimidine, and finally N- (4-acetylphenyl) -4- [2- ({ 4- [4- (piperidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 56.2%. EXAMPLE 11 preparation of N- (4-Acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (piperidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from piperidine, N-Boc-4-piperidone and p-fluoronitrobenzene, the key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloro-5-methylpyrimidine, and finally N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (piperidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 68.7%.
EXAMPLE 12 preparation of N- (4-Acetylphenyl) -4- [2- ({ 4- [4- (piperidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting with piperidine, N-Boc-4-piperidone and p-fluoronitrobenzene, the key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting with 2, 4-dichloropyrimidine, and finally N- (4-acetylphenyl) -4- [2- ({ 4- [4- (piperidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 64.5%. EXAMPLE 13 preparation of N- (4-Acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from N-ethylpiperazine, N-Boc-4-piperidone and p-fluoronitrobenzene, the key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2,4, 5-trichloropyrimidine, and finally N- (4-acetylphenyl) -4- [2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 69.1%.
EXAMPLE 14 preparation of N- (4-Acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized from N-ethylpiperazine, N-Boc-4-piperidone and p-fluoronitrobenzene according to the method of synthesis of 1.1-1.4 in example 1, the key intermediate L was synthesized from 2, 4-dichloro-5-methylpyrimidine according to the method of synthesis of 1.5-1.7 in example 1, and finally N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide according to the method of synthesis of 1.9 in example 1. The yield thereof was found to be 74.2%.
EXAMPLE 15 preparation of N- (4-Acetylphenyl) -4- [2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized from N-ethylpiperazine, N-Boc-4-piperidone and p-fluoronitrobenzene according to the 1.1-1.4 synthesis method in example 1, the key intermediate L was synthesized from 2, 4-dichloropyrimidine according to the 1.5-1.7 synthesis method in example 1, and finally N- (4-acetylphenyl) -4- [2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the 1.9 synthesis method in example 1. The yield thereof was found to be 70.5%.
EXAMPLE 16 preparation of N- (4-Acetylphenyl) -4- { 5-chloro-2- [ (4- {4- [ (2-hydroxyethyl) (methyl) amino ] piperidin-1-yl } phenyl) amino ] pyrimidin-4-yl } piperazine-1-carboxamide
The key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from N-methylethanolamine, N-Boc-4-piperidone and p-fluoronitrobenzene, the key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2,4, 5-trichloropyrimidine, and finally N- (4-acetylphenyl) -4- {2- [ (4- {4- [ (2-hydroxyethyl) (methyl) amino ] piperidin-1-yl } phenyl) amino ] pyrimidin-4-yl } piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 57.8%.
EXAMPLE 17 preparation of N- (4-Acetylphenyl) -4- { 5-chloro-2- [ (4- {4- [ (methyl) (propyl) amino ] piperidin-1-yl } phenyl) amino ] pyrimidin-4-yl } piperazine-1-carboxamide
The key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from N-methylpropylamine, N-Boc-4-piperidone and p-fluoronitrobenzene, the key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2,4, 5-trichloropyrimidine, and finally N- (4-acetylphenyl) -4- {2- [ (4- {4- [ (methyl) (propyl) amino ] piperidin-1-yl } phenyl) amino ] pyrimidin-4-yl } piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 57.5%.
EXAMPLE 18 preparation of N- (4-Acetylphenyl) -4- { 5-chloro-2- ({ 4- [3- (morpholin-4-yl) pyrrolidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
Key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from morpholine, N-Boc-3-pyrrolidone and p-fluoronitrobenzene, key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2,4, 5-trichloropyrimidine, and finally N- (4-acetylphenyl) -4- { 5-chloro-2- ({ 4- [3- (morpholin-4-yl) pyrrolidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 62.5%.
EXAMPLE 19 preparation of N- (4-Acetylphenyl) -4- { 5-chloro-2- [ (4- {3- [ (2-hydroxyethyl) (methyl) amino ] pyrrolidin-1-yl } phenyl) amino ] pyrimidin-4-yl } piperazine-1-carboxamide
N- (4-acetylphenyl) -4- { 5-chloro-2- [ (4- {3- [ (2-hydroxyethyl) (methyl) amino ] pyrrolidin-1-yl } phenyl) amino ] pyrimidin-4-yl } piperazine-1-carboxamide was synthesized from N-methylethanolamine, N-Boc-3-pyrrolidone and p-fluoronitrobenzene as raw materials according to the synthesis method of 1.1-1.4 in example 1, then 2,4, 5-trichloropyrimidine as raw materials according to the synthesis method of 1.5-1.7 in example 1, and finally N- (4-acetylphenyl) -4- { 5-chloro-2- [ (4- {3- [ (2-hydroxyethyl) (methyl) amino ] pyrrolidin-1-yl } phenyl) amino ] pyrimidin-4-yl } piperazine-1-carboxamide as the synthesis method of 1.9 in example 1. The yield thereof was found to be 66.5%.
EXAMPLE 20 preparation of N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from N-methylpiperazine, N-Boc-4-piperidone and p-fluoronitrobenzene, the key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloro-5-methylpyrimidine, and the N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] carbamic acid phenyl ester was synthesized according to the synthesis of 1.9 in example 1 starting from [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide. The yield thereof was found to be 53.6%. EXAMPLE 21 preparation of N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
N-methylpiperazine, N-Boc-4-piperidone and p-fluoronitrobenzene are used as raw materials, a key intermediate H is synthesized according to a synthesis method of 1.1-1.4 in the example 1, 2, 4-dichloropyrimidine is used as a raw material, a key intermediate L is synthesized according to a synthesis method of 1.5-1.7 in the example 1, and finally [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] carbamic acid phenyl ester is used as a raw material, and N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide is synthesized according to a synthesis method of 1.9 in the example 1. The yield thereof was found to be 56.7%.
EXAMPLE 22 preparation of N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from tetrahydropyrrole, N-Boc-4-piperidone and p-fluoronitrobenzene, the key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloro-5-methylpyrimidine, and the N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1 starting from phenyl [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide. The yield thereof was found to be 70.4%.
EXAMPLE 23 preparation of N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from N-ethylpiperazine, N-Boc-4-piperidone and p-fluoronitrobenzene, the key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloro-5-methylpyrimidine, and the N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] carbamic acid phenyl ester was synthesized according to the synthesis of 1.9 in example 1 starting from [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide. The yield thereof was found to be 62.1%.
EXAMPLE 24 preparation of N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
N-ethylpiperazine, N-Boc-4-piperidone and p-fluoronitrobenzene are used as raw materials, a key intermediate H is synthesized according to a synthesis method of 1.1-1.4 in the example 1, 2, 4-dichloropyrimidine is used as a raw material, a key intermediate L is synthesized according to a synthesis method of 1.5-1.7 in the example 1, and finally phenyl [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] carbamate is used as a raw material, and N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide is synthesized according to a synthesis method of 1.9 in the example 1. The yield thereof was found to be 64.3%.
EXAMPLE 25 preparation of N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H is synthesized by taking pyrrolidine, N-Boc-4-piperidone and p-fluoronitrobenzene as raw materials according to the synthesis method of 1.1-1.4 in the example 1, the key intermediate L is synthesized by taking 2, 4-dichloropyrimidine as raw materials according to the synthesis method of 1.5-1.7 in the example 1, and finally the N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide is synthesized by taking phenyl [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] carbamate as raw materials according to the synthesis method of 1.9 in the example 1. The yield thereof was found to be 54.2%.
EXAMPLE 26 preparation of N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
Key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from morpholine, N-Boc-4-piperidone and p-fluoronitrobenzene, key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloro-5-methylpyrimidine, and N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1 starting from phenyl [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] carbamate. The yield thereof was found to be 61.3%.
EXAMPLE 27 preparation of N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from morpholine, N-Boc-4-piperidone and p-fluoronitrobenzene, the key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloropyrimidine, and finally N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1 starting from phenyl [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] carbamate. The yield thereof was found to be 51.8%.
EXAMPLE 28 preparation of N- (4-Acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (4-acetylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
Key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from acetylpiperazine, N-Boc-4-piperidone and p-fluoronitrobenzene, key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloro-5-methylpyrimidine, and finally N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (4-acetylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 45.7%.
EXAMPLE 29 preparation of N- (4-Acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (thiomorpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
Key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from thiomorpholine, N-Boc-4-piperidone and p-fluoronitrobenzene, key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloro-5-methylpyrimidine, and finally N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (thiomorpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 53.1%.
EXAMPLE 30 preparation of N- (4-Acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (1-oxothiomorpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
Key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from 1-oxothiomorpholine, N-Boc-4-piperidone and p-fluoronitrobenzene, key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloro-5-methylpyrimidine, and finally N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (1-oxothiomorpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 56.4%.
EXAMPLE 31 preparation of N- (4-Acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (1, 2-dioxothiomorpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
Key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from 1, 2-dioxothiomorpholine, N-Boc-4-piperidone and p-fluoronitrobenzene, key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloro-5-methylpyrimidine, and finally N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (1, 2-dioxothiomorpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 52.5%.
EXAMPLE 32 preparation of N- (4-Acetylphenyl) -4- [ 5-methyl-2- ({ 5- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] pyridin-2-yl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from N-methylpiperazine, N-Boc-4-piperidone and 5-fluoro-2-nitropyridine, the key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloro-5-methylpyrimidine, and finally N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 5- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] pyridin-2-yl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 48.1%.
EXAMPLE 33 preparation of N- (4-Acetylphenyl) -4- [ 5-methyl-2- ({ 6- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] pyridin-3-yl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate H was synthesized according to the synthesis of 1.1-1.4 in example 1 starting from N-methylpiperazine, N-Boc-4-piperidone and 2-fluoro-5-nitropyridine, the key intermediate L was synthesized according to the synthesis of 1.5-1.7 in example 1 starting from 2, 4-dichloro-5-methylpyrimidine, and finally N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 6- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] pyridin-3-yl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the synthesis of 1.9 in example 1. The yield thereof was found to be 45.4%.
EXAMPLE 34 preparation of N- (4-Acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (1-methylpiperidin-4-yl) piperazin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
The key intermediate Q is synthesized according to the synthesis method of 1.1-1.4 in the example 1 by taking N-methylpiperidone, N-Boc-piperazine and p-fluoronitrobenzene as raw materials, the key intermediate S is synthesized according to the synthesis method of 1.5-1.7 in the example 1 by taking 2, 4-dichloro-5-methylpyrimidine as raw materials, and finally the N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (1-methylpiperidin-4-yl) piperazin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide is synthesized according to the synthesis method of 1.9 in the example 1. The yield thereof was found to be 67.8%.
EXAMPLE 35 preparation of N- (4-Acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (oxetan-3-yl) piperazin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide
Key intermediate Q was synthesized from oxetanone, N-Boc-piperazine and p-fluoronitrobenzene according to the method of synthesis of 1.1-1.4 in example 1, key intermediate S was synthesized from 2, 4-dichloro-5-methylpyrimidine according to the method of synthesis of 1.5-1.7 in example 1, and N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (oxetan-3-yl) piperazin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide was synthesized according to the method of synthesis of 1.9 in example 1. The yield thereof was found to be 55.5%.
The structures and 1 H-NMR and MS data of the compounds of the examples are shown in the following Table.
TABLE 1 Structure of the Compounds of examples and 1 H-NMR and MS data
The results of in vitro enzyme activity and cell antiproliferative activity of some of the compounds prepared according to the present invention are shown below
The compounds of the 2-aminopyrimidine skeleton of formula I according to the present invention were tested for in vitro JAK2, JAK3 and FLT3 kinase activity using Mobility SHIFT ASSAY.
The kinase buffer consisted of 50mM HEPEs (pH 7.5), 0.0015% BRIJ-35. Stop buffer contained a mixture of 100mM HEPES (pH 7.5), 0.015% BRIJ-35, 0.2% coating reagent #3 and 50mM EDTA. The initial concentration of the compounds was set at 100nM (JAK 2 and FLT 3) or 1000nM (JAK 3), and the test compounds were diluted with 100% DMSO to 50-fold the highest concentration required in the reaction. Dilutions of the test compounds (100 μl) were transferred to wells of a 96-well plate. Then, by adding 100mL DMSO to both wells as a control group, labeled as source plate. Transfer 10 μl of compound from the source plate to a new 96-well plate to prepare an intermediate plate. In the middle plate, an additional 90 μl of kinase buffer was added per well. The intermediate plate was shaken for 10min, and then 5 μl of each well on the 96-well intermediate plate was replicated as an assay plate onto 384-well plates. To each well in 384-well plates 10 μl of the prepared enzyme solution was added, followed by incubation at room temperature for 10min, and then 10 μl of the prepared peptide solution (FAM-labeled peptide and ATP in kinase-based buffer) was added. The samples were incubated at 28℃for 1h, then 30. Mu.L of stop buffer was added. The conversion data is copied from the Caliper program and converted to a suppression rate.
Inhibition (%) = (max-conversion)/(max-min) ×100.
IC 50 values were obtained using XLfit excel fitting data. Y=bottom+ (Top-Bottom)/(1+ (IC 50/X) ≡ HillSlope)
Results of in vitro kinase assays for some of the compounds are shown in tables 2-3.
TABLE 2
a Not determined.
TABLE 3 Table 3
Further, the above-described compound having a 2-aminopyrimidine skeleton was used for in vitro inhibition of the activity of human erythroleukemia cells HEL and human myelomonocytic leukemia cells MV 4-11.
After resuscitating and passaging for 2-3 times for stabilization, 10. Mu.L of the cell suspension is aspirated and counted in a cell counting plate, and the cell concentration is adjusted to 5X 10 4/mL. 100. Mu.L of the cell suspension or medium was placed in 96-well plates using Matrix 12 pipettor. And the remaining wells were filled with 200 μ LPBS, and different concentrations of the compound to be tested were added to the 96-well plates. After 72h incubation in the incubator, 22. Mu.L of Alamar-Blue solution was added to the 96-well plate and incubation was continued for 4h. The 96-well plate was shaken at room temperature for 10 seconds, and then absorbance at a wavelength of 530/590nm was measured with a microplate reader, and the inhibition ratio of cell growth was calculated according to the following formula:
Inhibition (%) = [ (control-a dosing)/(control-a blank) ]x100
IC 50 is the drug concentration required to inhibit half of the cell growth, and IC 50 was calculated using GRAPHPAD PRISM software throughput effect curve based on drug concentration and inhibition results.
The results of experiments on human erythroleukemia cells HEL and human acute monocytic leukemia cells MV4-11 of some compounds are shown in Table 4.
TABLE 4 Table 4
| Examples | HEL IC50(nM) | MV4-11 IC50(nM) |
| Example 1 Compounds | 567 | 6.8 |
| Example 5 Compounds | 644 | 9.43 |
| Example 6 Compounds | 1955 | 22.9 |
| Example 8 Compounds | 1105 | 6.08 |
| Example 14 Compounds | 1468 | 7.87 |
| Example 15 Compounds | 3206 | 15.4 |
| Fedratinib | 1425 | 79 |
Preliminary in vitro kinase test results show that the compound of the general formula I to be protected has good JAK2, FLT3 and the inhibition activities of mutant enzymes of the two, the selectivity of part of the compound to JAK3 is improved, part of the compound has the inhibition activities of JAK1 and TYK2, and meanwhile, the part of the compound is equivalent to or better than the positive control drug Fedratinib. Preliminary cell activity test results show that the compound of the general formula I to be protected by the invention has good cell activity, and part of the compounds are equivalent to the positive control drug Fedratinib.
Claims (15)
1. A 2-aminopyrimidine compound characterized by: the compound is a 2-aminopyrimidine compound shown in a general formula I and pharmaceutically acceptable salts, solvates or prodrugs thereof,
Wherein,
R 1 is independently selected from hydrogen, halogen, (C 1-C6) alkyl, (C 1-C6) haloalkyl;
Ar is (C 6-C10) aryl, 5-10 membered heteroaryl, optionally substituted with 1-3R 3, which may be the same or different;
R 3 is hydroxy, halogen, nitro, amino, cyano, (C 1-C6) alkyl, (C 1-C6) alkoxy, (C 1-C6) alkyl or (C 1-C6) alkoxy optionally substituted by hydroxy or amino or halogen, (C 1-C6) alkylamido, amino substituted by 1-2 (C 1-C6) alkyl groups, free or salified or esterified or amidated carboxy, (C 1-C6) alkylsulfinyl, (C 1-C6) alkylsulfonyl, (C 1-C6) alkanoyl, carbamoyl substituted by 1-2 (C 1-C6) alkyl, (C 1-C3) alkylenedioxy, (C 6-C10) aryl, (C 3-C10) cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocyclyl;
m and n are each independently an integer between 1 and 3;
Y and Z are each independently selected from N or CH;
X is N or CH;
R 2 is-NR 4R5 when X is CH, R 2 is a 4-10 membered heterocyclic group when X is N;
R 4 and R 5 are the same or different and are each independently selected from hydrogen, (C 1-C6) alkyl, (C 3-C7) cycloalkyl, (C 1-C6) alkanoyl, (C 1-C6) alkyl optionally substituted by hydroxy or amino or halogen; or R 4 and R 5 together with the N atom to which they are attached form a 4-10 membered heterocyclyl or a 5-10 membered heteroaryl;
The heterocyclic or heteroaryl groups in the foregoing R 2、R4 and R 5 are optionally substituted with 0-3R 6, which may be the same or different; the heterocyclic group or heteroaryl group optionally contains 1-4 heteroatoms which are the same or different and are selected from N, O, S, wherein the heterocyclic group optionally comprises 0-2 carbon-carbon double bonds or carbon-carbon triple bonds;
R 6 is oxo, halogen, (C 1-C6) alkyl or (C 1-C6) alkanoyl.
2. 2-Aminopyrimidines according to claim 1, wherein: the 2-aminopyrimidine compound shown in the general formula I and pharmaceutically acceptable salts, solvates or prodrugs thereof,
Wherein,
R 1 is independently selected from hydrogen, halogen, (C 1-C4) alkyl, (C 1-C4) haloalkyl;
Ar is (C 6-C10) aryl, 5-6 membered heteroaryl, optionally substituted with 1-3R 3, which may be the same or different;
R 3 is hydroxy, halogen, nitro, amino, cyano, (C 1-C4) alkyl, (C 1-C4) alkoxy, (C 1-C4) alkyl or (C 1-C4) alkoxy optionally substituted by hydroxy or amino or halogen, (C 1-C4) alkylamido, amino substituted by 1-2 (C 1-C4) alkyl groups, free or salified or esterified or amidated carboxy, (C 1-C4) alkylsulfinyl, (C 1-C4) alkylsulfonyl, (C 1-C4) alkanoyl, carbamoyl substituted by 1-2 (C 1-C4) alkyl, (C 1-C3) alkylenedioxy, (C 6-C10) aryl, (C 3-C7) cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl;
m and n are each independently an integer between 1 and 3;
Y and Z are each independently selected from N or CH;
X is N or CH;
R 2 is-NR 4R5 when X is CH, R 2 is a 4-10 membered heterocyclic group when X is N;
R 4 and R 5 are the same or different and are each independently selected from hydrogen, (C 1-C4) alkyl, (C 3-C7) cycloalkyl, (C 1-C4) alkanoyl, (C 1-C4) alkyl optionally substituted by hydroxy or amino or halogen; or R 4 and R 5 together with the N atom to which they are attached form a 4-6 membered heterocyclyl;
The heterocyclic groups in the foregoing R 2、R4 and R 5 are optionally substituted with 0 to 3R 6, which are the same or different; the heterocyclic group optionally contains 1-4 heteroatoms which are the same or different and are selected from N, O, S, and optionally contains 0-2 carbon-carbon double bonds or carbon-carbon triple bonds;
R 6 is oxo, halogen, (C 1-C6) alkyl, (C 1-C6) alkanoyl.
3. 2-Aminopyrimidines according to claim 2, characterized in that: the 2-aminopyrimidine compound shown in the general formula I and pharmaceutically acceptable salts, solvates or prodrugs thereof,
Wherein,
R 1 is independently selected from hydrogen, halogen, (C 1-C4) alkyl, trifluoromethyl;
Ar is (C 6-C10) aryl, 5-6 membered heteroaryl, optionally substituted with 1-3R 3, which may be the same or different;
R 3 is hydroxy, halogen, nitro, amino, cyano, (C 1-C4) alkyl, (C 1-C4) alkoxy, (C 1-C4) alkyl optionally substituted by hydroxy or amino or halogen or (C 1-C4) alkoxy, (C 1-C4) alkylamido, free or salified or esterified or amidated carboxy, (C 1-C4) alkylsulfinyl, (C 1-C4) alkylsulfonyl, (C 1-C4) alkanoyl, carbamoyl substituted by 1-2 (C 1-C4) alkyl, (C 1-C3) alkylenedioxy, (C 3-C6) cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl;
m and n are each independently 1 or 2;
Y and Z are each independently selected from N or CH;
X is CH;
R 2 is-NR 4R5;
R 4 and R 5 are the same or different and are each independently selected from hydrogen, (C 1-C4) alkyl, (C 3-C6) cycloalkyl, (C 1-C4) alkanoyl, (C 1-C4) alkyl optionally substituted by hydroxy, amino or halogen; or R 4 and R 5 together with the N atom to which they are attached form a 4-6 membered heterocyclyl;
The heterocyclic groups in the foregoing R 2、R4 and R 5 are optionally substituted with 0 to 3R 6, which are the same or different; the heterocyclic group optionally contains 1-4 heteroatoms which are the same or different and are selected from N, O, S, and optionally contains 0-2 carbon-carbon double bonds or carbon-carbon triple bonds;
R 6 is oxo, halogen, (C 1-C4) alkyl, (C 1-C4) alkanoyl.
4. A 2-aminopyrimidine compound as claimed in claim 3 wherein: the 2-aminopyrimidine compound shown in the general formula I and pharmaceutically acceptable salts, solvates or prodrugs thereof,
Wherein X is C;
m and n are the same or different and are 1 or 2;
r 1 is independently selected from hydrogen, halogen, (C 1-C4) alkyl, trifluoromethyl;
Ar is (C 6-C10) aryl, 5-6 membered heteroaryl, optionally substituted with 1-3R 3, which may be the same or different;
R 3 is hydroxy, halogen, nitro, amino, cyano, (C 1-C4) alkyl, (C 1-C4) alkoxy, (C 1-C4) alkyl optionally substituted by hydroxy, amino or halogen or (C 1-C4) alkoxy, (C 1-C4) amino substituted by 1-2 (C 1-C4) alkyl, (C 1-C4) alkylamido, free or salified or esterified or amidated carboxy, (C 1-C4) alkylsulfinyl, (C 1-C4) alkylsulfonyl, (C 1-C4) alkanoyl, carbamoyl substituted by 1-2 (C 1-C4) alkyl, (C 1-C3) alkylenedioxy, (C 3-C6) cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl;
Y and Z are each independently selected from N or CH;
R 4 and R 5 are the same or different and are each independently selected from (C 1-C4) alkyl, (C 1-C4) alkyl optionally substituted by hydroxy; or R 4 and R 5 together with the N atom to which they are attached form a 4-6 membered heterocyclyl;
The heterocyclic group is optionally substituted with 0 to 3 identical or different R 6; the heterocyclic group optionally contains 1-4 heteroatoms which are the same or different and are selected from N, O, S, and optionally contains 0-2 carbon-carbon double bonds or carbon-carbon triple bonds;
R 6 is oxo, halogen, (C 1-C4) alkyl, (C 1-C4) alkanoyl.
5. The 2-aminopyrimidine compound of claim 4 wherein: the 2-aminopyrimidine compound shown in the general formula I and pharmaceutically acceptable salts, solvates or prodrugs thereof,
Wherein,
R 1 is independently selected from hydrogen, halogen, (C 1-C4) alkyl;
Ar is phenyl optionally substituted with 1 to 3R 3, which may be the same or different;
X is C;
m and n are the same or different and are 1 or 2;
R 3 is hydroxy, halogen, nitro, amino, cyano, (C 1-C4) alkyl, (C 1-C4) alkoxy, (C 1-C4) alkyl optionally substituted by hydroxy, amino or halogen or (C 1-C4) alkoxy, (C 1-C4) alkylamido, free, salified, esterified and amidated carboxy, (C 1-C4) alkylsulfinyl, (C 1-C4) alkylsulfonyl, (C 1-C4) alkanoyl, (C 1-C4) alkylcarbamoyl, (C 1-C3) alkylenedioxy, imidazolyl, pyrazolyl, triazolyl, oxazolyl, isoxazolyl, oxadiazolyl;
Y and Z are CH;
R 4 and R 5 are the same or different and are each independently selected from (C 1-C4) alkyl, (C 1-C4) alkyl optionally substituted by hydroxy; or R 4 and R 5 together with the N atom to which they are attached form
6. 2-Aminopyrimidines of the general formula I:
n- (4-acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- (4-acetylphenyl) -4- [2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- (4-acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- (4-acetylphenyl) -4- [2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- (4-acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (piperidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (piperidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [2- ({ 4- [4- (piperidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- (4-acetylphenyl) -4- [ 5-chloro-2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [ 5-methyl-2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- [2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- { 5-chloro-2- [ (4- {4- [ (2-hydroxyethyl) (methyl) amino ] piperidin-1-yl } phenyl) amino ] pyrimidin-4-yl } piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- { 5-chloro-2- [ (4- {4- [ (methyl) (propyl) amino ] piperidin-1-yl } phenyl) amino ] pyrimidin-4-yl } piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- { 5-chloro-2- ({ 4- [3- (morpholin-4-yl) pyrrolidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- (4-acetylphenyl) -4- { 5-chloro-2- [ (4- {3- [ (2-hydroxyethyl) (methyl) amino ] pyrrolidin-1-yl } phenyl) amino ] pyrimidin-4-yl } piperazine-1-carboxamide;
n- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (4-ethylpiperazin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
N- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (pyrrolidin-1-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [ 5-methyl-2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide;
n- [4- (1, 3, 4-oxadiazol-2-yl) phenyl ] -4- [2- ({ 4- [4- (morpholin-4-yl) piperidin-1-yl ] phenyl } amino) pyrimidin-4-yl ] piperazine-1-carboxamide.
7. A 2-aminopyrimidine compound as claimed in any one of claims 1 to 6 wherein: the compound salt is a salt formed with an acid selected from the group consisting of: hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, trifluoroacetic acid or aspartic acid.
8. A pharmaceutical composition characterized by: the composition comprises a compound of formula I as defined in any one of claims 1 to 7, and a pharmaceutically acceptable salt, solvate or prodrug thereof.
9. Use of a compound according to claim 1, characterized in that: use of a compound according to any one of claims 1 to 7, and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, in the manufacture of a medicament for the prevention or treatment of a disease associated with a JAK kinase inhibitor.
10. Use of a compound according to claim 1, characterized in that: use of a compound according to any one of claims 1 to 7, and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, for the manufacture of a medicament for the prevention or treatment of diseases associated with FLT3 kinase inhibitors.
11. Use according to any one of claims 9-10, characterized in that: the diseases include: inflammatory bowel disease and hematological malignancies.
12. The use according to claim 11, wherein: the hematological malignancy includes: leukemia, myelodysplastic syndrome, malignant lymphoma, multiple myeloma, and myeloproliferative diseases.
13. The use according to claim 12, wherein: the leukemia comprises: acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphoblastic leukemia, and chronic myeloid leukemia.
14. The use according to claim 12, wherein: the myeloproliferative disease includes: polycythemia vera, chronic myelogenous leukemia, primary thrombocythemia and myelofibrosis.
15. The use according to claim 11, characterized in that: the inflammatory bowel disease includes: ulcerative colitis and Crohn's disease.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211399109.8A CN118005609A (en) | 2022-11-09 | 2022-11-09 | 2-Aminopyrimidine compound and application thereof |
| PCT/CN2023/129613 WO2024099229A1 (en) | 2022-11-09 | 2023-11-03 | 2-aminopyrimidine compound and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211399109.8A CN118005609A (en) | 2022-11-09 | 2022-11-09 | 2-Aminopyrimidine compound and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118005609A true CN118005609A (en) | 2024-05-10 |
Family
ID=90941672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211399109.8A Pending CN118005609A (en) | 2022-11-09 | 2022-11-09 | 2-Aminopyrimidine compound and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN118005609A (en) |
| WO (1) | WO2024099229A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100015353A (en) * | 2007-04-02 | 2010-02-12 | 팔라우 파르마 에스에이 | Pyrrolopyrimidine derivatives as jak3 inhibitors |
| JP2011518219A (en) * | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | Inhibitors of protein kinases |
| RU2019131017A (en) * | 2013-10-21 | 2019-11-25 | Мерк Патент Гмбх | Heteroaryl Compounds as BTK Inhibitors and Their Use |
| KR101577430B1 (en) * | 2014-03-06 | 2015-12-14 | 한국화학연구원 | piperidine-3,5-dicarboxamide derivatives and pharmaceutical composition for anti cancer containing the same as an active ingredient |
| NO2721710T3 (en) * | 2014-08-21 | 2018-03-31 | ||
| CN110317176A (en) * | 2019-07-04 | 2019-10-11 | 沈阳药科大学 | 2- amino-metadiazine compound and application thereof |
-
2022
- 2022-11-09 CN CN202211399109.8A patent/CN118005609A/en active Pending
-
2023
- 2023-11-03 WO PCT/CN2023/129613 patent/WO2024099229A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024099229A1 (en) | 2024-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102073854B1 (en) | Compounds and compositions for modulating egfr mutant kinase activities | |
| CN110317176A (en) | 2- amino-metadiazine compound and application thereof | |
| JP6114820B2 (en) | Pteridinone derivatives and applications as inhibitors of EGFR, BLK, FLT3 | |
| EP2828259B1 (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
| CN115057855B (en) | Substituted five-membered and six-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof | |
| US10800741B2 (en) | Quinoline compound, preparation method and medical use therefor | |
| CN113717156B (en) | EGFR inhibitor, preparation method and application thereof | |
| CN113896710A (en) | SHP2 inhibitor and application thereof | |
| EP3786157B1 (en) | Phenyl triazole mll1-wdr5 protein-protein interaction inhibitor | |
| JP2019520367A (en) | Novel Heterocyclic Derivative Compound and Use Thereof | |
| EP3696176B1 (en) | Novel phenylpyridine derivative and pharmaceutical composition containing same | |
| CN109575045B (en) | Thienopyrimidine compound, preparation method thereof, medicinal composition and application thereof | |
| US10308654B2 (en) | Preparation and use of kinase inhibitor | |
| KR20020010482A (en) | Novel N-triazolylmethyl-piperazine derivatives as neurokinin-receptor antagonists | |
| US20230133169A1 (en) | Egfr inhibitor, composition, and method for preparation thereof | |
| CN106467540B (en) | Application of pteridinone derivative as FLT3 inhibitor | |
| CN118005609A (en) | 2-Aminopyrimidine compound and application thereof | |
| US20180186815A1 (en) | Pharmaceutical compositions, methods for their preparation and their use in the treatment of cancer | |
| KR102409595B1 (en) | Novel purinone derivatives as protein kinase CSF-1R inhibitor | |
| CN114728963B (en) | Novel triazolopyridine derivatives and pharmaceutical compositions comprising the same | |
| AU2018278284A1 (en) | Carboxylic acid derivatives of pyridoquinazolines useful as protein kinase inhibitors | |
| KR20180122493A (en) | Novel TYRO 3 inhibitory compounds, preparation method thereof, pharmaceutical composition for use in preventing or treating TYRO 3 relating diseases containing the same as an active ingredient | |
| KR101721128B1 (en) | Ureidobenzothiazole derivatives and pharmaceutical compositions for preventing or treating cancer containing the same | |
| CN118812513A (en) | Benzimidazole derivative and application thereof | |
| KR20140143329A (en) | Novel Maleic acid derivatives, preparation method thereof, and anti-cancer compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |